Jason Luoma (@jasonluoma) header
Jason Luoma (@jasonluoma) profile picture

I am a psychologist, scientist, and entreprenuer studying shame, psychedelics, compassion, and belonging.

Portland, Oregon
Joined May 2009
Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)Photo by Jason Luoma (@jasonluoma)
Applications now open for psilocybin training retreats for healthcare professionals! Combining Acceptance and Commitment Therapy principles with psychedelic science, these week-long immersive experiences are reshaping professional development. #psychedelicscience 🧵
2
4
249
Why this matters: As psychedelic therapy moves toward legalization, there's an urgent need for properly trained healthcare professionals who understand both the clinical AND experiential aspects of this work. This is rare hands-on training in a legal, structured setting.
2
2
125
#ACBSWC We are happy to announce that the call for submissions for the ACBS World Conference 2025 in New Orleans, Louisiana, USA is now open! We are now accepting submissions for symposia, papers, panels, workshops, ignite sessions, and posters. The deadline to submit is February 15, 2025, the poster deadline is March 20, 2025. Learn more here: zurl.co/95df
2
1
5
751
Lykos Therapeutics Provides Statement on Recent FDA Meeting. The brief, 100-word statement says a team from Lykos met with FDA re: next steps for its MDMA NDA. 'Path forward' includes additional Phase 3 and potential independent third-party review of prior Ph 3 clinical data.
1
5
1
11
3,067
Reasons authors give for not sharing data when their paper says "data available upon request" nature.com/articles/s41597-0…
17
88
39
366
80,308
Here's some advice for (new) reviewers from a now ex-editor: Please avoid creating unnecessary work for authors, editors and ultimately readers by trying to become an (unlisted) co-author with your own preferences and wishes 1/9
1
14
2
44
5,722
Re: the quintessential presumed-to-be genetic disorder: "Since the initial results became available.. NIMH has spent almost $8 billion..Not a single gene has been found that can be causally linked to schizophrenia & the research has produced no improvements in treatments" 1/2
12
60
6
166
20,232
What does psychedelic therapy look like in the underground? Who is providing it? We explore this in: "Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use". tandfonline.com/doi/full/10.…
This Post is from an account that no longer exists. Learn more
3
3
30
2,514
Jason Luoma retweeted
In this post, I tried to lay out, in a non-technical way, where we are in the development of AI, the state of the top five AI models available now, & what the near future of AI is going to be The short answer is that LLMs are going to keep getting better. oneusefulthing.org/p/scaling…
30
158
19
833
88,034
Jason Luoma retweeted
1
1
1
365
Podcast on a systematic review of adverse events in classic psychedelic research studies with Hopkins Psychiatry Resident Jared Hinkle MD/PhD (@jaredhinkle4) and CPCR Faculty David Yaden (@existwell). The authors discuss the urgent need for improvement of adverse event data recording and reporting in psychedelic research (and other fields) and call for more standardized reporting. They also break down the findings of their review: edhub.ama-assn.org/jn-learni…
3
10
1
34
3,118
Important new paper
This quoted post is unavailable.
1
143
THE ROLE OF PSYCHOLOGICAL FLEXIBILITY IN PSYCHEDELIC EFFECT ON DEPRESSIVE SYMPTOMS - "Qualitative analyses identify psychological flexibility as a mediator of psychedelics’ therapeutic effect on depressive symptoms" goo.gl/scholar/xxVVDa
5
1
27
1,680
Psilocybin Bipolar II study: most participants met remission criteria 3 weeks after a single 25-mg psilocybin dose, and most remained in remission 12 weeks post-dose with no increase in mania/hypomania symptoms or suicidality. jamanetwork.com/journals/jam…
10
26
2
99
7,486
Today, we announce our decision to reorganize Lykos Therapeutics in effort to focus on addressing FDA’s recent decision on our investigational treatment option for adults with PTSD. Learn more here: news.lykospbc.com/2024-08-15…
4
1
17
4,491